Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

Inclusion Criteria: * Male or female, Age ≥ 18 years * Have a histological or cytological confirmed solid tumor malignancy * Patient scheduled to receive their first course of anthracycline cyclophosphamide (AC) based chemotherapy regimen or Moderately Emetogenic Chemotherapy for the treatment of solid malignant tumor * Patient scheduled to receive CINV prevention with AKYNZEO® or Standard of Care according to the summary of product characteristics based on the judgement of their investigator's * Naïve of CT * ECOG performance up to 2 * Able to read, understand and follow the study procedures * Patient with Health insurance Exclusion Criteria: * Pregnancy and breastfeeding women; * Hypersensitivity to active substances, excipients or other ingredients of Akynzeo® or Emend®; * Protected patients: majors under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision